Molidustat for the treatment of anemia in Japanese patients undergoing peritoneal dialysis: a single‐arm, open‐label, phase 3 study

This 36‐week, open‐label, single‐arm, phase 3 study investigated the safety and efficacy of molidustat in Japanese patients with renal anemia undergoing peritoneal dialysis. Molidustat was titrated every 4 weeks to maintain Hb levels within the target range (≥11.0 and <13.0 g/dL). The primary eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Akizawa, Tadao, Nobori, Kiyoshi, Matsuda, Yoshimi, Taki, Kentaro, Hayashi, Yasuhiro, Hayasaki, Takanori, Yamamoto, Hiroyasu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290504/
https://www.ncbi.nlm.nih.gov/pubmed/34310049
http://dx.doi.org/10.1111/1744-9987.13713

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290504/
https://www.ncbi.nlm.nih.gov/pubmed/34310049
http://dx.doi.org/10.1111/1744-9987.13713

Ejemplares similares